OR WAIT null SECS
August 07, 2023
BlueRock will be responsible for the global development and commercialization of therapeutic candidates emerging from this collaboration.
July 31, 2023
The new facility is set to utilize and extend SCG's capabilities in advanced cell therapy manufacturing and off-the-shelf human-induced Pluripotent Stem Cell (iPSC) technology.
July 20, 2023
The document’s recommendations outline what studies and reports are required for changes to cell and gene therapy manufacturing.
July 03, 2023
Manufacturers face the challenge of meeting growing demand for personalized biopharmaceuticals.
July 02, 2023
A novel complement therapeutic CTx001 offers a novel approach to treating geographic atrophy.
June 26, 2023
The companies hope address the need for efficient collection, cryopreservation, quality control, and logistics capabilities of leukapheresis materials to support various aspects of the cell therapy workflow.
June 22, 2023
The new headquarters located in Columbus, Ohio, more than triples Andelyn Biosciences’ footprint to meet growing demand for CGT services.
June 15, 2023
Charles River’s off-the-shelf lentiviral vector packaging plasmids are intended for use with cell and gene therapies.
May 31, 2023
The start of production of US engineering batches of NXC-201, a CAR-T cell therapy candidate in early clinical development, is the first step in transferring Nexcella’s existing manufacturing process to the United States.
Under the new MTA and Option License Agreement, Adcendo can nominate ADCs against two novel ADC targets, according to the press release.